2024 Speakers

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Philip is CSO at Step Pharma, a French therapeutic biotech focused on novel targeted approaches for the treatment of cancer. Prior to joining Step Pharma, Philip held senior leadership roles in biotech and biopharma companies, overseeing oncology drug development and biomarker discovery...

Dr. Nicola Beltraminelli joined Innate Pharma as Vice President and Chief Development Officer in January 2022.  Dr. Beltraminelli brings more than 20 years of biotech experience to the role, and specifically in the development of biologic products from early discovery to GMP manufacture. Most...

Phil has over 20 years’ experience in biopharmaceutical R&D and has held senior operational and leadership roles in the development of novel antibody therapeutics. He began his career at the Glaxo Institute of Applied Pharmacology and GlaxoWellcome before gaining biologics expertise at...

Sara Bonetti is a Scientist at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Sara obtained her PhD in Biochemistry and Molecular Biology from the University of Bern, Switzerland, where...

Professor Brockwell is an academic in the School of Molecular and Cellular Biology and a member of the Astbury Centre at the University of Leeds in the UK.  He undertook his undergraduate studies (Pharmacy) and PhD at the University of Manchester, before joining Leeds first as post-doctoral...

Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for...

Patrick Chames obtained his phD at the "University de la Méditerranée", Marseille, France in 1997 in the field of antibody engineering. From 1997 to 2001, he worked in the laboratory of phage display pioneer Hennie R. Hoogenboom where he isolated by phage display the first human antibody...

Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she collaborates to the "Antibodies to watch" editorials in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody...

Anne De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in...

A biochemist by training, Achim has been working with bispecific antibodies or ADCs and technology development for their effective screening. In one flavour, screening of such and further complex NBEs is realized applying versatile microfluidics and in part in conjunction with mammalian libraries...

Cyrille Dreyfus is a Protein Biochemist who has more than 10 years of combined industry and academic experience in large molecule drug discovery. He holds a PhD in Protein Engineering and Structural Biology from the CEA (French Alternative Energies and Atomic Energy Commission). In 2010, Cyrille...

I graduated at the department of biochemistry at the Technical University of Darmstadt and did my phD in the field of antibody discovery and engineering in the working group of Prof. Harald Kolmar. I joined Merck in Darmstadt for a PostDoc project establishing microfluidic systems for antibody...

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in ...

Professor Torbjörn Gräslund holds a Ph.D. in Biotechnology from KTH - Royal Institute of Technology, Sweden, since 2001. After two years of post-doc training with Professor Carlos Barbas at the Scripps Research Institute, he has been principal investigator at the Department of Protein Science at...

Since two years, Francois leads the Biologics Analytical Characterization Mass Spectrometry group within Technical Research & Development at Novartis Pharma AG located in Basel, Switzerland. His group focuses on the characterization of novel biologics entities as well as their degradation...

Anissa Harbi is an Immunologist MD from Annaba, Algeria, with a strong background in clinical research and patient care. Currently serving as an Immunologist at Les Hôpitaux d'Alger, Anissa is dedicated to advancing medical knowledge and improving patient outcomes.

James has over 15 years’ experience focusing on the formulation sector. Working at Croda he has focused on utilising Croda Pharma’s range of excipients and bioprocessing aids used in pharmaceutical formulations and processes. Previously, James led the new surfactant and formulation development...

Rüdiger Jankowsky, Ph.D. is a seasoned life science entrepreneur with broad experience in product development and licensing in the biotech and healthtech industry. He served as CEO for several start-ups, built interdisciplinary expert organizations for R&D and licensing and was instrumental in...

Masters in political science from the University of Copenhagen 45 years of professional experience, including: Head of section in the Ministries of Social Affairs and of LabourLabour Counsellor at the Danish UN-mission in GenevaHealth Counsellor at the Danish EU-representation in BrusselsSpokesman ...

Dr. Hans Keirstead is an internationally recognized stem cell expert and successful entrepreneur. Known for developing treatments for quadriplegic spinal cord injury, cancer therapies for melanoma, brain, and ovarian cancers, and a multi-pathogen vaccine, he has also advanced therapeutic research...

Dr. Rinse Klooster is the Director of the Early Antibody Discovery team at Merus NV, the Netherlands. In his current role, he is responsible for the generation of all antigen-specific common light chain based Fab panels that form the basis of Merus’ multispecific antibody platform. Several of these ...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research. For the last 19 years Dan has been working with analytical development in the biopharmaceutical...

Britta Lipinski is a PhD candidate in the Antibody Discovery and Protein Engineering Department of Merck KGaA, supervised by Stefan Zielonka, where she works in close collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research focuses on the...

Robin Löving, Chief Scientific Officer (CSO) at Salipro Biotech. Robin has more than 15 years’ experience working with therapeutically interesting membrane proteins. He did his PhD with a focus on membrane proteins and antigen design at the Karolinska Institute in Stockholm, Sweden. After being...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

Björn Niebel is a Senior Principal Scientist, Lab Head in the Discovery Department of the Nanobody Research Platform at Sanofi Ghent. Björn received his master’s degree in Chemistry from the University of Braunschweig, Germany in 2006 and holds a PhD in Biochemistry from the University of...

Mark Petersen is a senior scientist in the medical chemistry in ADC therapeutic development group at Zymeworks, where he is has contributed to and lead the development of multiple cytotoxic ADC platforms.  Prior to joining Zymeworks in 2017, Mark studied natural product synthesis in the lab of...

Dr. Simon Plyte has over 20 years’ experience in research and development in the Pharma industry, both in Big Pharma and small Biotech. He has worked on the discovery and development of NCEs and Biologics, predominantly in the field of Oncology but has also worked in...

Philipp Probst is Associate Director of ADC Research at Araris Biotech AG, a Swiss biotech company located in Au ZH pioneering a novel linker technology for antibody-drug conjugates. He studied Pharmaceutical Sciences and received his PhD from ETH Zürich in 2018, where he worked in the group of...

I am heading a research group at the department of Protein science at the KTH School of Engineering sciences in Chemistry, Biotechnology and Health. We are a young group with four great PhD students, two excellent technicians, one extraordianary fantastic labmanager and two researchers. Our...

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of...

Rune did his PhD on ion mobility mass spectrometry at University of Southern Denmark in a collaboration with Novo Nordisk and graduated in 2012. Since then he has worked in therapeutic protein and antibody discovery research focusing on biophysical characterization and developability. In 2018 he...

Simone Schmitt has over 13 years of experience in antibody development and discovered more than 5 best-in-class antibodies. Pior to building the microfluidic high-troughput B cell cloning and screening platform at Memo Therapeutics she worked at Delenex Therapeutics. Simone holds a PhD in...

Lei Shi, PhD. is an SVP at Biointron. Prior to that, he worked for a series of biotech companies, including Virtuoso Therapeutics, Zai Lab, and Bird Rock. Lei had also worked at J&J in antibody discovery technology. He completed his Postdoc study at MGH and Harvard Medical School.

Philipp Spycher is the co-founder and CEO of Araris Biotech AG. Philipp incorporated Araris after winning the PSI Founder Fellowship as well as several other prices and grants to commercialize the Araris Linker Technology. During his post-doctoral work at the Paul Scherrer Institute...

2015-2020: Scientist at Genentech,Since 2020: Head of Biology / VP, Biology and Translational Research at TubulisScientific training background: molecular cell biology, protein degradation, cellular protein homeostasis

Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. From 2001-2008, Bj?rn was team leader in the biotech company Pharmexa A/S, responsible for molecular cloning and expression of protein-based drug...

Natascha Wuillemin, Executive VP Immunology, has joined Mabylon in August 2015 driven by her interest in immunotherapy and allergic diseases in particular. She has a Master degree in Pharmaceutical Sciences (ETH Zurich) and a PhD in Immunology (University of Bern). During her PhD and post-doctoral...

Che Yang is a specialist in protein engineering group at Novo Nordisk, with a particular focus on applying cutting-edge computational method and GenAI for design of mini-protein and antibody for the treatment of various diseases. He has been involved in scientific outreaching with emerging KOL in...

Iwan Zimmermann is one of the founders and Chief Scientific Officer of Linkster Therapeutics. Iwan has over 12 years of experience with single domain antibodies and the biology of ion channels and transporters. Prior to co-founding Linkster Therapeutics, Iwan conducted research as platform leader...